News

The U.S. Food and Drug Administration (FDA) has approved Revolution Medicines’ RASONQUE (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic adenocarcinoma…
Read More...

REGENXBIO has provided an update on RGX-121, its investigational gene therapy for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The company said it does not…
Read More...

Lundbeck has received orphan designation from the European Commission for asedebart (Lu AG13909), an experimental monoclonal antibody being developed to treat Cushing’s syndrome of…
Read More...

Takeda has received approval in Japan for ORZEYFUL (oveporexton), a new oral treatment for adults with narcolepsy type 1 (NT1), a rare neurological disorder that causes excessive…
Read More...

GSK has received approval in Japan for Hibsago (bepirovirsen), an antisense oligonucleotide (ASO) treatment designed to provide a functional cure for chronic hepatitis B (CHB) in…
Read More...

Gossamer Bio has entered into an agreement with new and existing institutional investors to raise up to approximately $250 million through a private placement. The funding will support…
Read More...

Genentech, a member of the Roche Group, plans to invest approximately $750 million to build a new device fill-finish manufacturing facility at its campus in Hillsboro, Oregon. The…
Read More...

Piramal Pharma has completed the acquisition of an additional 40.67% stake in Yapan Bio, a Hyderabad-based contract development and manufacturing organization (CDMO) focused on vaccines…
Read More...

Charles River Laboratories and Medigen Vaccine Biologics have entered into a collaboration to support the development of Medigen’s next-generation multivalent enterovirus vaccine.…
Read More...

WellSpan Health and Johns Hopkins Medicine are expanding their oncology collaboration to improve access to advanced cancer care, specialist expertise and clinical research for patients…
Read More...

SandboxAQ has announced the general availability of AQPotency, an AI-powered model designed to help drug discovery teams predict how strongly potential drug molecules may act on disease…
Read More...

Ultragenyx Pharmaceutical has received accelerated approval from the U.S. Food and Drug Administration (FDA) for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for…
Read More...

Kynexis, a clinical-stage biotechnology company developing treatments for cognitive problems linked to brain diseases, has raised €40 million in a Series A financing extension. The…
Read More...

Regeneron Pharmaceuticals has received U.S. Food and Drug Administration approval for Pasatru (garetosmab-grts), a new treatment for adults living with fibrodysplasia ossificans…
Read More...

Consano Bio has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for C-1101, an investigational treatment being developed for chronic, painful…
Read More...

BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal aimed at adding a potential new treatment for hypophosphatasia (HPP), a rare genetic bone disease, to its…
Read More...

Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger that will create a company focused on developing new treatments for migraine and other headache…
Read More...

LEO Pharma has agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma in a deal that could reach up to $435 million in upfront and near-term milestone payments.…
Read More...

Sandoz and Shanghai Henlius Biotech have entered into a major collaboration to develop, manufacture and commercialize biosimilar medicines, with the aim of expanding access to…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig for the treatment of patients with advanced and metastatic biliary…
Read More...